The Role of Narcotic Antagonists in the Rehabilitation of Opiate Addicts: A Review of Naltrexone

References

• Martin W. R., Gorodetzky C. W., McClane T. K. A proposed method for ambulatory treatment of narcotic addicts using a long-acting, orally effective narcotic antagonist cyclazocine. An experimental study, in Committee on Problems of Drug Dependence222. National Research Council, Washington, D.C. 1965
   Google Scholar
• Martin W. R., Gorodetzky C. W., McClane T. K. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther 1966; 7: 455
   PubMed Web of Science ®Google Scholar
• Martin W. R. The basis and possible utility of the use of opioic antagonists in the ambulatory treatment of the addict. The Addictive States, A. Wikler. Williams and Wilkins, Baltimore 1968; 367
   Google Scholar
• Wikler A. Conditioning factors in opiate addiction and relapse. Narcotics, D. M. Wilner, G. G. Kassebaum. McGraw-Hill, New York 1965; 85
   Google Scholar
• Wikler A. Some duplications of conditioning therapy for problems of drug abuse. Behav. Sci 1971; 16: 92
   PubMedGoogle Scholar
• Wikler A., Pescor F. T. Classical conditioning of morphine abstinence, reinforcement of opoid-drinking behavior, and relapse in morphine addicted rats. Psychopharmacologia 1967; 10: 255
   PubMedGoogle Scholar
• Wikler A. Requirements for extinction of relapse facilitating variables and for rehabilitation in a narcotic antagonist treatment program. Adv. Biochem. Pharmacol 1974; 8: 399
   Google Scholar
• Jaffe J. H., Brill L. Cyclazocine: A long acting narcotic antagonist: Its voluntary acceptance as a treatment modality by narcotics abusers. Int. J. Addict 1966; 1: 99
   Web of Science ®Google Scholar
• Freedman A., Fink M., Sharoff R., Zaks A. Clinical studies of cyclazocine in the treatment of narcotic addiction. Am. J. Psychiatry 1968; 124(11)1499
   PubMed Web of Science ®Google Scholar
• Luckom-Nurnberg F., Kissin B. Cyclazocine treatment: A two-year follow up, in Drug Abuse. Modern Trends, Issues and Perspectives, A. Schecter, E. Kaufman, H. Alksne. Dekker, New York 1978
   Google Scholar
• Fink M., Freedman A. M., Zaks A. M., Resnick R. B. Narcotic antagonists: Another approach to addiction therapy. Am. J. Nurs 1971; 71(7)1359
   PubMedGoogle Scholar
• Chappell J. N., Jaffe J. H., Sevoy E. C. Cyclazocine in a multimodality treatment program: Comparative results. Int. J. Addict 1971; 6: 509
   Google Scholar
• Jasinski D. R., Martin W. R., Haertzen C. A. The human pharmacology and abuse potential of N-allyinoroxy morphine (naloxone). J. Pharmacol. Exp. Ther 1967; 157: 420
   PubMed Web of Science ®Google Scholar
• Fink M., Zaks A., Sharoff R., Mora A., Bruner A., Levit S., Freedman A. M. Naloxone in heroin dependence. Clin. Pharmacol. Ther 1968; 9: 568
   PubMed Web of Science ®Google Scholar
• Naloxone in the management of the narcotic abuse. A pilot study, in Proceedings of the Committee on Problems of Drug Dependence, A. A. Kurland, F. Kerhan. National Academy of Science-National Research Council, Washington, D.C. 1971; 1462
   Google Scholar
• Zaks A., Jones T., Fink M., Freedman A. M. Naloxone treatment of opiate dependence. J. Am. Med. Assoc March 29, 1971; 215(13)2108
   PubMed Web of Science ®Google Scholar
• Freedman A., Zaks A., Resnick R., Fink M. Blockade with methadone, cyclazocine and naloxone. Int. J. Addict 1970; 5(3)507
   PubMed Web of Science ®Google Scholar
• Kurland A. A., Hanlon T. E. Naloxone and narcotic abuses: A controlled study of partial blockade. Int. J. Addict 1974; 9(5)663
   PubMed Web of Science ®Google Scholar
• Kurland A. A., McCabe L., Hanlon T. Contingent naloxone treatment of the narcotic addict: A pilot study. Int. J. Addict 1976; 11(1)131
   PubMed Web of Science ®Google Scholar
• Kleber H. D. Clinical experiences with narcotic antagonists. Opiate Addiction: Origin and Treatment, S. Fisher, A. M. Freedman. Winston, Washington, D. C. 1976; 211
   Google Scholar
• Blumberg H., Pachter I. N., Matossian Z. U.S. Patent July, 1967; 3: 322–950
   Google Scholar
• Blumberg H., Dayton H. B., Wolf P. S. Analgesic and narcotic antagonist properties of noroxymorphine derivatives. Toxicol. Appl. Pharmacol 1967; 10: 406
   Google Scholar
• Martin W. R., Jasinski D. R., Mansky P. A. Presented to the Committee on Problems of Drug Dependence. Characteristics of the Blocking Effects of EN-1639A (N-Cycloproplmethyl-7,8-dihydro-14-hydroxnormorphine HCI). National Research Council, Toronto 1971
   Google Scholar
• Martin W. R., Jasinski D. R. Characterization of EN-1639A. Clin. Pharmacol. Ther 1973; 14: 142
   Google Scholar
• Martin W. R., Jasinski D. R., Mansky P IA. Naltrexone, an antagonist for the treatment of heroin dependence effects in man. Arch. Gen. Psychiatry 1973; 28: 784
   PubMed Web of Science ®Google Scholar
• Short-term effects of naltrexone: a progress report. Proceedings of the Committee on Problems of Drug Dependence, R. Resnick, J. Volavka, A. M. Freedman. National Academy of Sciences-National Research Council, Washington, D.C. 1974; 250
   Google Scholar
• Resnick R., Volavka J., Freedman A. M., Thomas M. Studies of EN-1639A (naltrexone): A new narcotic antagonist. Am. J. Psychiatry 1974; 131: 646
   PubMed Web of Science ®Google Scholar
• Naltrexone in a clinical setting: Preliminary observations. Proceedings of the Committee on Problems of Drug Dependence, A. J. Schecter, D. J. Grossman. National Academy of Sciences-National Research Council, Washington, D.C. 1974; 264
   Google Scholar
• Schecter A. J., Grossman B. A. Experience with naltrexone. A suggested role in drug abuse treatment programs, in Developments in the Field of Drug Abuse, E. Senay, V. Shorty, H. Alksne. Schenkman, Cambridge, Massachusetts 1974; 754
   Google Scholar
• Schecter A., Friedman J., Grossman D. Clinical use of naltrexone (EN-1639A): Efficacy and safety in pilot studies. Am. J. Drug Alcohol Abuse 1974; 1: 253
   PubMed Web of Science ®Google Scholar
• Schecter A. Clinical use of naltrexone (EN-1639A), II. Experience with the first 50 patients in a New York City treatment clinic. Am. J. Drug Alcohol Abuse 1975; 2: 433
   PubMed Web of Science ®Google Scholar
• Jacohson R. Endo Pharmaceutical Laboratories. Personal Communication.
   Google Scholar
• Resnick R. B., Schuyten-Resnick E. A point of view concerning treatment approaches with narcotic antagonists, in Narcotic Antagonists. Naltrexone Progress Report Research Monograph Series No. 9, D. Julius, P. Renault. Department of Health, Education, and Welfare, (ADM), Rockville, Maryland 1976; 84, National Institute on Drug Abuse, 76 -387
   Google Scholar
• Resnick R., Kestenbaum R. S., Washton A., Poole D. Naloxone precipitated withdrawal: A method for rapid induction onto naltrexone. Clin. Pharmacol. Ther 1977; 21: 409
   PubMed Web of Science ®Google Scholar
• Kurland A. A., McCabe L. Rapid detoxification of the narcotic addict with naloxone hydrochloride. A preliminary report. J. Clin. Pharmacol 1976; 16: 66
   PubMedGoogle Scholar
• O'Brien C. P., Greenstein R. A., Mintz J., Woody G. E. Clinical experience with naltrexone. Am. J. Drug Alcohol Abuse 1975; 2: 365
   PubMed Web of Science ®Google Scholar
• Lewis D. C. The clinical usefulness of narcotic antagonists: Preliminary findings of the use of naltrexone. Am. J. Drug Alcohol Abuse 1975; 2: 403
   PubMed Web of Science ®Google Scholar
• Curran S., Savage C. Patient response to naltrexone: Issues of acceptance treatment effects and frequency of administration, in Narcotic Antagonists. Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 67
   Google Scholar
• O'Brien C., Greenstein R. Naltrexone in a behavioral treatment program, in Narcotic Antagonists. Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 136
   Google Scholar
• Taintor Z., Landsberg R., Wicks N., Plumb M., D'Amanda C., Greenwood J. Experiences with naltrexone in Buffalo. Am. J. Drug Alcohol Abuse 1975; 2: 391
   PubMed Web of Science ®Google Scholar
• Curran S., Savage C. Patient response to naltrexone. Issues of acceptance treatment effects and frequency of administration, in Narcotic Antagonists, D. Julius, P. Renault. (Research Monograph Series No. 9), Naltrexone Progress Report Department of Health, Education, and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 67
   Google Scholar
• Keegan J., Lavenducki C., Schooff K. Comments and findings from a naltrexone double-blind study. Narcotic Antagonists: Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 74
   Google Scholar
• Haas N., Ling W., Holmes E., Blakis M., Litaker M. Naltrexone in methad-done maintenance patients electing to become “drug free”. Narcotic Antagonists: Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 70
   Google Scholar
• Hurzeler M., Gerwitz M. S., Kleber H. Varying clinical contexts for administering naltrexone. Narcotic Antagonists: Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 48
   Google Scholar
• Meyer R. E., Mirin S. M., Altman J. L. The clinical usefulness of narcotic antagonists: Implications of behavioral research. Am. J. Drug Alcohol Abuse 1975; 2: 417
   PubMed Web of Science ®Google Scholar
• Meyer R. E., Mirin S. M., Altman J., McNamee H. B. A behavioral paradigm for the evaluation of narcotic antagonists. Arch. Gen. Psychiatry 1976; 33: 371
   PubMed Web of Science ®Google Scholar
• Meyer R. E., McNamee H. B., Mirin S. M., Altman J. L. Analysis and modification of opiate reinforcement. Int. J. Addict 1976; 11(3)467
   PubMed Web of Science ®Google Scholar
• Altman J. L., Meyer R. E., Mirin S. M., McNamee H. B. Opiate antagonists and the modification of heroin self-administration in man: An experimental study. Int. J. Addict, 11(3 467)1976
   Google Scholar
• Rawlins M., Randall M., Meyer R. E., McNamee H. B., Mirin S. M. Aftercare on narcotic antagonists: Prospects and problems. Int. J. Addict 1976; 11(3)501
   PubMed Web of Science ®Google Scholar
• Laboratory modification of heroin acquisition: Implications for narcotic antagonist treatment. Proceedings of the Conference for Biomedical Research in Narcotic-Abuse Problems, J. Altman. Vancouver, British Columbia, Canada 1974
   Google Scholar
• Callahan E., Rawson R., Glazer M., McCleave B., Arias R. Comparison of two naltrexone treatment programs: Naltrexone above versus naltrexone plus behavior therapy. Narcotic Antagonists: Naltrexone Progress Report, D. Julius, P. Renault. Research Monograph Series No. 9, National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-387, Rockville, Maryland 1976; 150
   Google Scholar
• Brahen L. S., Capone T., Weichert V., Babinski A., Desiderio D. A comparison of controlled clinical and laboratory studies of the narcotic antagonists cyclazocine and naltrexone. Drug Abuse: A National Perspective, A. Schecter, E. Kaufman, H. Alksne. Dekker, New York 1978
   Google Scholar
• Brahen L. S., Weichert V., Babinski R. N. The first narcotic antagonist jail work-release program for addicted inmates. Developments in the Field of Drug Abuse, E. Senay, V. Shorty, H. Alksne. Schenkman, Cambridge Massachusetts 1974; 769
   Google Scholar
• Brahen L. S. Naltrexone study guidelines: “Good vehicle-wrong destination”. Am. J. Drug Alcohol Abuse 1975; 2: 451
   PubMed Web of Science ®Google Scholar
• Goldstein A. On the role of chemotherapy in the treatment of heroin addiction. Am. J. Drug Alcohol Abuse 1975; 2: 279
   PubMed Web of Science ®Google Scholar
• Goldstein A. Heroin addiction, sequential treatments employing pharmacologic supports. Arch. Gen. Psychiatry 1976; 33: 353
   PubMed Web of Science ®Google Scholar
• Parwatikar J., Crawford J., Unverdi C. Antagonist study in St. Louis. Am. J. Drug Alcohol Abuse 1975; 2: 379
   PubMed Web of Science ®Google Scholar
• Amon D., Kissin B., Solomon J. Psychological indicators of success in cyclozocine treatment. Drug Abuse: A National Perspective, A. Schecter, E. Kaufman, H. Alksne. Dekker, New York 1978
   Google Scholar
• Robins L. N., Murphy G. E. Drug use in a normal population of young Negro. men, Am. J. Public Health 1967; 57(9)1580
   PubMed Web of Science ®Google Scholar
• Winick C. Careers of chronic heroin users. Drug Use: Epidemiological and Sociological Approaches, E. Josephson, E. Caroil. Wiley-Halsted, New York 1974; 105
   Google Scholar
• Winick C. Maturing out of narcotic addiction. Bull. Narc 1962; 14(1): 1
   Google Scholar
• Robins L. N. Special Action Office for Drug Abuse Prevention. The Vietnam Drug User Returns. U.S. Government Printing Office, Washington, D.C. 1973
   Google Scholar
• Robins L. N. Department of Psychiatry. Veterans' Drug Use Three Years after Vietnam. Washington University School of Medicine. 1975, mimeograph.
   Google Scholar
• Kleinman P. H., Lukoff I. E. Ethnic differences in factors related to drug use. J. Health Soc. Behav. In Press.
   Google Scholar
• O'Donnell J. A., Voss H. L., Clayton R. R., Slatin G. T., Room R. G.W. Young Men and Drugs: A Nationwide Survey. National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-311. Research Monograph Series No. 5, National Technical Information Service, Springfield, Virginia 1976
   Google Scholar
• Vaillant G. E. A twelve year follow-up of New York narcotic addicts, IV. Some characteristics and determinants of abstinence. Am. J. Psychiatry 1966; 123((5))573
   PubMedGoogle Scholar
• Vaillant G. E. A 20 year follow-up of New York narcotic addicts. Arch. Gen. Psychiatry 1973; 29: 237
   PubMed Web of Science ®Google Scholar
• Nurco D. N., Bonito A. J., Learner N., Baltes M. B. Studying addicts over time: Methodology and preliminary findings. Am. J. Drug Alcohol Abuse 1975; 2(2)183
   PubMed Web of Science ®Google Scholar
• Zinberg N. E., Harding W. M., Stelmack S. M., Marblestone R. A. Patterns of heroin use. Advances in Clinical Pharmacology of Drug Dependence. New York Academy of Sciences, Washington, D.C. November, 1977
   Google Scholar
• Harding W. M., Zinberg N. E., Stelmack S. M., Barry M. D. Formerly Addicted, Now Controlled Heroin Users. Paper Presented at the National Drug Abuse Conference, San Francisco, 1977
   Google Scholar
• Narcotic Antagonists: The Search for Long-Acting Preparations. Research Monograph Series No. 4, R. Willette. National Institute on Drug Abuse, Department of Health, Education, and Welfare, (ADM) 76-296, Rockville, Maryland 1975
   Google Scholar